tradingkey.logo
tradingkey.logo
Search

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

ReutersApr 8, 2026 12:13 PM
facebooktwitterlinkedin

- BioXcel Therapeutics Inc BTAI.O:

  • BIOXCEL THERAPEUTICS ANNOUNCES ENROLLMENT OF FIRST PATIENTS IN U.S. DEPARTMENT OF WAR-FUNDED STUDY OF BXCL501 (SUBLINGUAL DEXMEDETOMIDINE) FOR TREATMENT OF ACUTE STRESS REACTIONS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI